[Translation] A randomized, open-label, single-dose, two-sequence, two-period, crossover bioequivalence study of olopatadine hydrochloride granules in healthy Chinese subjects under fasting and postprandial administration conditions.

主要目的本试验以广州市桐晖药业有限公司提供的盐酸奥洛他定颗粒（规格：2.5mg）为受试制剂，以原研单位協和キリン株式会社生产的盐酸奥洛他定颗粒（商品名：Allelock，规格：0.5%(2.5mg/0.5g)）为参比制剂，分别考察空腹和餐后状态下受试制剂与参比制剂在健康试验参与者体内的药代动力学参数，评价两制剂的生物等效性。次要目的观察受试制剂和参比制剂在健康试验参与者中的安全性。

[Translation]

Primary Objective: This study used olopatadine hydrochloride granules (2.5 mg) provided by Guangzhou Tonghui Pharmaceutical Co., Ltd. as the test formulation and olopatadine hydrochloride granules (trade name: Allelock, 0.5% (2.5 mg/0.5 g)) manufactured by Kyowa Kirin Co., Ltd. as the reference formulation. The pharmacokinetic parameters of the test and reference formulations in healthy participants under fasting and postprandial conditions were investigated to evaluate their bioequivalence. Secondary Objective: To observe the safety of the test and reference formulations in healthy participants.

Start Date07 Jul 2026

Sponsor / Collaborator

Guangzhou Tosun Pharmaceutical Co., Ltd.

CTR20261267

/ CompletedNot Applicable

盐酸奥洛他定口崩片在空腹和餐后条件下的人体生物等效性试验

[Translation] Bioequivalence studies of orally disintegrating olopatadine hydrochloride tablets in humans under fasting and postprandial conditions.

主要研究目的：本研究以海南科进生物制药有限公司提供的盐酸奥洛他定口崩片（规格：5mg）为受试制剂，以原研厂家協和キリン株式会社持证的盐酸奥洛他定口崩片（规格：5mg，商品名：Allelock®）为参比制剂，评价受试制剂和参比制剂在空腹及餐后条件下给药后的生物等效性。次要研究目的：观察单次口服5mg的盐酸奥洛他定口崩片受试制剂或参比制剂在健康试验参与者中的安全性。

[Translation]

Primary objective: This study evaluated the bioequivalence of olopatadine hydrochloride orally disintegrating tablets (5 mg) supplied by Hainan Kejin Biopharmaceutical Co., Ltd., and olopatadine hydrochloride orally disintegrating tablets (5 mg, trade name: Allelock®) certified by Kyowa Kirin Co., Ltd., under fasting and postprandial administration conditions. Secondary objective: To observe the safety of a single oral dose of 5 mg olopatadine hydrochloride orally disintegrating tablets (test or reference formulation) in healthy trial participants.

Start Date25 Apr 2026

Sponsor / Collaborator

Kirgen Biological Pharmaceutical(Hainan) Co., Ltd.

CTRI/2026/03/106415

/ Not yet recruitingPhase 3IIT

A Randomized Controlled Trial to study the efficacy of Rasanjanadi Bidalaka and Olopatadine eye drop in Vataja Abhishyanda with reference to Allergic Conjunctivitis - NIL

Start Date15 Apr 2026

Sponsor / Collaborator-

100 Clinical Results associated with Olopatadine Hydrochloride

100 Translational Medicine associated with Olopatadine Hydrochloride

100 Patents (Medical) associated with Olopatadine Hydrochloride

579

Literatures (Medical) associated with Olopatadine Hydrochloride

01 Sep 2026·Journal of the American Medical Directors Association

The Association Between Prospective Payment System and Post-Acute Care Outcomes Among Traditional Medicare Beneficiaries in Inpatient Rehabilitation Facilities

Article

Author: Kuo, Wan-Chin ; Ouayogodé, Mariétou H ; Mullahy, John ; Luo, Dian ; Burns, Marguerite E ; Cao, Ying Jessica

OBJECTIVES:

To assess whether Prospective Payment System (PPS)-regulated expected length of stay (eLOS) affects actual length of stay (aLOS) and subsequent post-acute care (PAC) outcomes among traditional Medicare beneficiaries.

DESIGN:

Data from the Inpatient Rehabilitation Facility-Patient Assessment Instrument for 2019 to 2020 were analyzed.

SETTING AND PARTICIPANTS:

184,202 Medicare beneficiaries aged 65 and older were admitted to inpatient rehabilitation facilities for stroke, hip fracture, cardiac, or joint replacement.

METHODS:

We used a 2-way fixed-effects instrumental variable approach based on a cross-sectional study. Exposure is the aLOS, which is instrumented by eLOS based on Centers for Medicare & Medicaid Services-defined case-mix groups and comorbidity tiers. Primary outcomes are functional improvements (mobility and cognitive scores), discharge destination (home, home with home health, and skilled nursing facility), and successful community return (discharge to home or home health).

RESULTS:

Among the 184,202 beneficiaries, 85,737 were admitted for a stroke, 54,763 for a hip fracture, 28,151 for a cardiac condition, and 15,551 underwent joint replacement. The mean age was 78.2 years (56.8% female) before the COVID-19 pandemic and 78.4 years (57.3% female) during the pandemic. eLOS was significantly associated with aLOS across all conditions. Each additional day of aLOS was significantly associated with increases of 4.39% to 4.51% in mobility scores and 2.96% to 3.70% in cognitive scores for patients with stroke, hip fracture, and cardiac disease. Longer LOS also increased the likelihood of returning to the community among patients with stroke (odds ratio [OR], 1.073; P < .01), hip fracture (OR, 1.199; P < .01), and cardiac condition (OR, 1.095; P < .01) patients but had no significant effect among patients who underwent joint replacement.

CONCLUSIONS AND IMPLICATIONS:

PPS-regulated eLOS influences aLOS and affects PAC outcomes differently. These findings support the role of PPS in improving care delivery and advancing health care equity in PAC.

14 Jul 2026·CIRCULATION

GPRASP1 Safeguards Endothelial Aspartate Metabolism to Prevent Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

Article

Author: Alimu, Xiayidan ; Tang, Yushan ; Hu, Miaoqing ; Wei, Xiaoyi ; Hu, Pengyan ; Wang, Xiaojian ; Lv, Cheng ; Wang, Yibo ; Zhang, Yanan ; Zhang, Yu ; Li, Ruofei ; Ding, Yuqin

BACKGROUND::

Pulmonary hypertension (PH) is a serious complication of heart failure with preserved ejection fraction (HFpEF), for which no targeted therapies are currently available. Endothelial dysfunction plays a crucial role in PH associated with HFpEF (PH-HFpEF), yet its molecular drivers remain poorly defined.

METHODS::

Transcriptome profiling uncovered endothelial characteristics of PH-HFpEF. Endothelial-specific GPRASP1 (GPCR [G protein–coupled receptor]–associated sorting protein 1 deletion in mice was conducted to investigate its participation in PH-HFpEF pathology. Multimodal metabolomics, isotope tracing, proteomics, and mechanistic biochemical assays were used to map downstream pathways and identify druggable mediators.

RESULTS::

GPRASP1 was significantly lowered in pulmonary endothelial cells of PH-HFpEF models. Endothelial Gprasp1 knockout mice exhibited major PH-HFpEF features, including pulmonary vascular remodeling, elevated pulmonary pressure, diastolic dysfunction, and abnormal glucose/lipid metabolism. GPRASP1 loss impaired tricarboxylic acid cycle activity by stabilizing ASNS (asparagine synthetase), preferentially shifting aspartate toward asparagine synthesis over oxaloacetate production. This metabolic reprogramming led to adenosine triphosphate depletion, reactive oxygen species accumulation, endothelial nitric oxide synthase uncoupling, and nitric oxide deficiency. We discovered that, beyond its classic role in GPCR sorting, GPRASP1 functioned as a noncanonical adaptor protein that scaffolded the E3 ubiquitin ligase PRKN (Parkin) and ASNS, promoting PRKN-dependent K48-linked ubiquitination and proteasomal degradation of ASNS via its C-terminal domain. In parallel, under mitochondrial stress, GPRASP1 strengthened PRKN interactions with MFN1/2, enhanced their K63-linked ubiquitination, and facilitated PRKN-mediated mitophagy. Restoration of GPRASP1 expression or pharmacological inhibition of ASNS activity with olopatadine normalized aspartate utilization, improved mitochondrial bioenergetics, rescued endothelial function, and attenuated cardiopulmonary pathology in PH-HFpEF models.

CONCLUSIONS::

Our findings unlocked a noncanonical role of GPRASP1 in preserving pulmonary endothelial homeostasis and delineated a novel GPRASP1-PRKN-ASNS axis that connected proteostasis with endothelial metabolic integrity, highlighting aspartate metabolism as a targetable vulnerability in cardiopulmonary disease.

01 Jul 2026·Brazilian Journal of Otorhinolaryngology

Olopatadine plus mometasone for seasonal allergic rhinitis treatment: A pooled analysis of clinical trials

Article

Author: Anselmo-Lima, Wilma Terezinha ; Gordonsmith, Roger Hereward ; Carbone, Luis Felipe Barreiras ; Wu, Wen ; Aggarwal, Vineet ; Nakanishi, Marcio ; Barkate, Hanmant

OBJECTIVE:

This study was conducted to analyze the efficacy and safety of a fixed-dose combination of olopatadine HCl (antihistamine) and mometasone furoate (corticosteroid) (Olo/Mom, GSP301) for the treatment of Seasonal Allergic Rhinitis (SAR).

METHODS:

Efficacy data from one phase II (NCT02318303 [GSP301-201]) and two pivotal phase III double-blind, randomized, active, placebo-controlled (NCT02631551 [GSP301-301] and NCT02870205 [GSP301-304]) clinical trials were collated and analyzed. These studies investigated Olo/Mom (administered twice daily/BID) compared with placebo and its monotherapy constituents for the treatment of SAR in patients aged ≥12-years. In addition, safety data were analyzed from the aforementioned studies and a proof-of-concept study (NCT03444506 [GSP301-POC]). Primary and secondary endpoints were compared between Olo/Mom, its active mometasone and olopatadine constituents, and placebo.

RESULTS:

For the efficacy analyses (n = 2971), Olo/Mom significantly reduced rTNSS scores compared with placebo (Least Square Mean Difference [LSMD = -0.94]; 95% CI: -1.17, -0.70; p < 0.0001), olopatadine (LSMD = -0.37; 95% CI: -0.60, -0.14; p = 0.0019), and mometasone (LSMD = -0.42; 95% CI: -0.65, -0.18; p = 0.0005). Olo/Mom also significantly improved the RQLQ and iTNSS scores compared with placebo and its monotherapy constituents (p < 0.05, all). The onset of action of Olo/Mom was observed at 15-minutes and was sustained at subsequent timepoints. The incidence of treatment-emergent adverse events in the Olo/Mom, placebo, olopatadine, and mometasone groups was 13.9%, 9.5%, 13.2%, and 7.9%, respectively.

CONCLUSION:

This pooled analysis demonstrated the superiority of Olo/Mom compared to its monotherapy constituents or placebo in reducing SAR symptoms over 14-days. Moreover, this study showed that Olo/Mom has a rapid onset of action and significantly improves RQLQ scores compared to placebo. Administration of Olo/Mom BID is an effective and well-tolerated option for the treatment of SAR in patients aged 12-years or older.

LEVEL OF EVIDENCE:

I (Level I - randomized controlled trials).

News (Medical) associated with Olopatadine Hydrochloride

04 Jun 2026

·www.prnewswire.com

Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10

SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly-owned subsidiary of Kexing Biopharm. Designed to treat neovascular age-related macular degeneration (nAMD), the progress of GB10 marks a significant milestone in the Company's accelerating innovative drug R&D pipeline. GB10 is a high-concentration, ophthalmic protein drug formulation independently developed by Shenzhen Kexing. It features a bispecific antibody targeting both VEGF and Ang-2. With a high concentration of 140 mg/mL, GB10 Injection allows for a smaller injection volume or higher dosage, thereby extending the dosing interval. It is expected to achieve a "once per four months" dosing schedule, significantly improving patient compliance. Preclinical data indicate international competitiveness of GB10 Injection in terms of both biological activity and in vivo efficacy. In a laser-induced choroidal neovascularization (CNV) monkey model, it demonstrated effective inhibition of pathological ocular neovascularization in the fundus. Neovascular age-related macular degeneration (nAMD) remains a leading cause of blindness globally among individuals aged over 50. Driven by the rapid growth of the internet, increased screen time, and an aging population, the clinical demand for ophthalmic treatments is surging. Therapeutic regimens with extended dosing intervals address critical clinical pain points, such as high injection frequency and poor patient compliance. Kexing Biopharm is simultaneously accelerating its independent R&D of dual-target antibody ophthalmic pipeline and actively introducing externally developed ophthalmic products for international markets, including Aflibercept biosimilars and Olopatadine Hydrochloride eye drops. These efforts aim to expand its global footprint and drive internationalization through continuous innovation. Looking ahead, the Company will adhere to its philosophy of "Precise Products, Predictable Effects, Health Protection," providing high-quality and accessible treatment options to patients worldwide. SOURCE Kexing Biopharm 21% more press release views with Request a Demo

Phase 1

04 Jun 2026

·allsci.com

Kexing’s launches first-in-human testing for dual VEGF-Ang-2 BsAb in wAMD

China-based Kexing Biopharm has dosed the first subject in a Phase I clinical trial of GB10, a bispecific antibody (BsAb) targeting both VEGF and Angiopoietin-2 (Ang-2) for neovascular age-related macular degeneration (nAMD). The GB10 clinical trial, conducted through wholly-owned subsidiary Shenzhen Kexing Pharmaceutical, marks the company’s first wholly-owned novel ophthalmic drug to reach human testing, according to a press release. The molecule is formulated at 140 mg/mL — higher than Roche’s VEGF/Ang-2 BsAb Vabysmo (faricimab)’s 120 mg/mL and VEGF antibody Eylea (aflibercept) 8 mg’s 114.3 mg/mL — and is designed to achieve a once-every-four-months intravitreal dosing schedule. According to Kexing, preclinical data in a laser-induced choroidal neovascularization monkey model demonstrated inhibition of pathological fundus neovascularization. Kexing’s molecule enters a field already reshaped by Roche’s faricimab, the first approved dual VEGF/Ang-2 bispecific for nAMD, and high-dose aflibercept 8 mg (Eylea HD, Regeneron/Bayer), both of which support up to 16-week dosing intervals. GB10 shares faricimab’s dual-target rationale but employs a structurally distinct VEGF-Trap fused to an anti-Ang-2 single-domain VHH antibody, rather than a full bispecific IgG format. For Kexing, GB10 anchors an ophthalmic innovation strategy that also includes an aflibercept biosimilar and olopatadine hydrochloride eye drops, pairing novel mechanisms with commercial-stage products. The company’s most advanced asset, GB05 — a recombinant human interferon α1b inhalation solution for pediatric RSV — is in Phase III in China with US FDA IND clearance obtained in 2025, demonstrating a broader internationalization ambition that GB10 may eventually follow. Whether GB10’s concentration advantage translates into a clinically meaningful durability benefit over faricimab will depend on Phase I pharmacokinetic data and, ultimately, registrational trial design. The dual VEGF/Ang-2 mechanism is validated; the differentiation question is one of degree. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 1Drug ApprovalINDPhase 3

05 May 2026

·www.businesswire.com

BlinkRx Announces Availability of RYALTRIS ® for Convenient Home Delivery Following Glenmark’s Commercial Transition

NEW YORK--(BUSINESS WIRE)--BlinkRx, the digital pharmacy platform designed to make prescription medications more accessible and affordable, today announced that RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal Spray, 665 mcg/25 mcg* per spray, is now available for fulfillment through the BlinkRx platform. This follows Glenmark Pharmaceuticals Inc., USA’s transition to direct commercialization and distribution of the product. Patients can now access RYALTRIS® through BlinkRx’s streamlined digital platform as allergy season peaks nationwide. As seasonal allergies reach peak levels in many parts of the country, BlinkRx is helping ensure that patients across the United States can access RYALTRIS® quickly and conveniently. While RYALTRIS® is not available through traditional retail pharmacy channels, patients can benefit from a seamless, end-to-end experience through BlinkRx that includes the best available price and free home delivery. “At BlinkRx, our mission is to ensure that essential medications are easily within reach for everyone. We’re excited to be expanding availability of RYALTRIS® on our platform during the worst seasonal allergies in many parts of the country,” said Geoff Chaiken, co-founder and CEO of BlinkRx. “We are pleased to expand access to RYALTRIS® through BlinkRx, which offers a convenient option for patients,” said Marc Kikuchi, President & Business Head, North America at Glenmark Pharmaceuticals Inc., USA. “As we continue to advance our direct commercialization efforts in the U.S., partnerships like these play a key role in improving how patients access and experience care.” RYALTRIS® is indicated for the treatment of symptoms associated with seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.1 It is a fixed-dose combination nasal spray that brings together olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) in a single formulation. With demand for allergy relief increasing during the spring season, ensuring reliable and convenient access to effective therapies remains a priority for both providers and patients. Patients interested in finding out if RYALTRIS® is right for them should speak with their healthcare provider to learn more. Patients with existing RYALTRIS® prescriptions can ask their pharmacist to transfer the prescription to BlinkRx. About BlinkRx BlinkRx is redefining the pharmacy experience with integrated data-driven technology that improves patient access to branded medications. Its prescription journey management platform streamlines every step of the process, improving the prescription journey across all stakeholders. Patients enjoy the lowest network price, free home delivery, and personalized support. Healthcare providers benefit from dedicated access teams and enhanced prior authorization support for their patients. Pharmacies are able to access technologies that improve their ability to serve patients. And pharmaceutical manufacturers gain greater transparency from prescription to fulfillment. Learn more at www.blinkrx.com. About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research‐led, pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high-quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com *Calculated on the anhydrous basis 1RYALTRIS® Nasal Spray approved prescribing information, Glenmark Specialty SA, Switzerland. Please click here to view full prescribing information, including Important Safety Information. For additional information about RYALTRIS® and how to access, please visit us.ryaltris.com. RYALTRIS is a registered trademark of Glenmark Specialty SA.

100 Deals associated with Olopatadine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01192	Olopatadine Hydrochloride	R01AC08 S01GX09	DB00768

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Rhinitis, Allergic, Seasonal	United States	Novartis Pharmaceuticals Corp.	15 Apr 2008
Allergic rhinoconjunctivitis	Japan	Novartis Pharma KK	26 Jul 2006
Seasonal allergic conjunctivitis	European Union	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	16 May 2002
Seasonal allergic conjunctivitis	Iceland	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	Liechtenstein	Novartis Europharm Ltd.	16 May 2002
Seasonal allergic conjunctivitis	Norway	Novartis Europharm Ltd.	16 May 2002
Pruritus	Japan	Kyowa Kirin Co., Ltd.	22 Dec 2000
Rhinitis, Allergic	Japan	Kyowa Kirin Co., Ltd.	22 Dec 2000
Urticaria	Japan	Kyowa Kirin Co., Ltd.	22 Dec 2000
Conjunctivitis, Allergic	United States	Alcon Laboratories, Inc.	18 Dec 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Perennial allergic conjunctivitis	Phase 3	-	Alcon Research Ltd.	01 Jan 2012
Acute conjunctivitis	Phase 3	-	Alcon Research Ltd.	01 Oct 2009
Rhinitis, Allergic, Perennial	Phase 3	United States	Alcon Research Ltd.	01 Dec 2006
Rhinoconjunctivitis	Phase 3	-	Alcon Research Ltd.	18 Apr 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


APAO2019	Not Applicable	Vernal Keratoconjunctivitis	96	Olopatadine 0.1%	qfrblyyasy(xjejbgyvmz) = jzckglzsov huepdowcnb (vzmexzekdi )	Positive	06 Mar 2019
				Sodium Cromoglycate 2%	qfrblyyasy(xjejbgyvmz) = imbgwytuhy huepdowcnb (vzmexzekdi )
AAAAI2019	Not Applicable	Rhinitis, Allergic, Seasonal	-	GSP301 (olopatadine 665μg/mometasone 25μg BID)	fruhlscxbr(zvxjiadvcg) = ebnqearvfm kvfssjcdpl (nlyycaycpo, -0.41 to -0.05)	-	01 Feb 2019
NCT00609128 (CTgov)	Not Applicable	Conjunctivitis, Allergic \| Lacerations	21	olopatadine	rfyicfrfxw(vgypdmhyfo) = iabidwhnxg lhkvhbmeie (npaibdhzer, wulvztjtij - sizdqxoajf) View more	-	20 Sep 2018
AAAAI2018	Not Applicable	Rhinitis, Allergic, Seasonal	-	GSP301 (olopatadine 665μg/mometasone 25μg BID)	xujdbyvczy(pftzbioqwr) = ijennznqsz paepylqfvx (avygafhzkz, -0.35[-0.63 - -0.07])	-	01 Feb 2018
ARVO2015	Phase 3	-	448	Olopatadine 0.77%	sqwfcoxgfd(stbmmgjmvg) = bxdpnvybrk pjwustdhqo (bjwaonjcya )	Positive	01 Jun 2015
				Olopatadine 0.1%	sqwfcoxgfd(stbmmgjmvg) = epapjndgnh pjwustdhqo (bjwaonjcya )
NCT01697969 (CTgov)	Phase 4	Conjunctivitis, Allergic	17	Olopatadine hydrochloride (Left Eye)	sifwzsydlo(cxwohevldj) = lpjjlnjsjh clhejmgqvm (wvfteoltmx, 0.85) View more	-	18 Aug 2014
				Olopatadine hydrochloride (Right Eye)	sifwzsydlo(cxwohevldj) = dyzmpalutw clhejmgqvm (wvfteoltmx, 0.92) View more
NCT01743027 (CTgov)	Phase 3	Conjunctivitis, Allergic \| Perennial allergic conjunctivitis	902	AL-4943A ophthalmic solution (AL-4943A)	xhtexglyxl(kutpioymvp) = qgcsgsmkhc waksckfest (hkckkohfot, 0.069) View more	-	11 Aug 2014
				Olopatadine hydrochloride ophthalmic solution, 0.2% (PATADAY)	xhtexglyxl(kutpioymvp) = deamfjjdbe waksckfest (hkckkohfot, 0.069) View more
NCT01698814 (CTgov)	Phase 3	Conjunctivitis, Allergic	518	AL-4943A Ophthalmic Solution (AL-4943A)	zwenmrzgyb = qnhrpboxje gywqvlrrfq (fxqsmkejsb, shjibvebhc - clfejtmemo) View more	-	28 Feb 2014
				AL-4943A Ophthalmic Solution (AL-4943A Vehicle)	zwenmrzgyb = cdihqdbcbe gywqvlrrfq (fxqsmkejsb, vvnsnypwzy - njwosxnxxb) View more
NCT01732757 (CTgov)	Phase 4	Acute conjunctivitis \| Conjunctivitis, Allergic	157	Alcaftadine 0.25% (Lastacaft®)	snylxvcykd(hrlncyozyt) = zsvmtmnmlm xvcifhngqq (fxzslgxcmk, 0.582) View more	-	14 Jan 2014
				Olopatadine 0.2% (Pataday™)	snylxvcykd(hrlncyozyt) = vhmtjfijhg xvcifhngqq (fxzslgxcmk, 0.752) View more
NCT01007253 (CTgov)	Phase 4	Rhinitis, Allergic, Seasonal	21	PL (PL/PL)	tkagmblpmn(uhlakdurzf) = mftskjipmb mtnbkvzjzc (dnqpudzcrz, kawbfqsydl - uqfsotmcsr) View more	-	17 Jul 2013
				fluticasone furoate (FF)+PL (FF/PL)	tkagmblpmn(uhlakdurzf) = lwmtyjmkxr mtnbkvzjzc (dnqpudzcrz, wazexjckfa - fpjglmltja) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis